AXSM Axsome Therapeutics, Inc.
Price Chart
Executive Summary
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including post-hoc efficacy analyses and a network meta-analysis comparing SYMBRAVO to gepants for acute migraine treatment. This is a routine scientific conference update with no new regulatory or financial catalysts.
Actionable Insight
This is a routine medical conference update with no material new data or regulatory catalyst. Monitor for any subsequent peer-reviewed publications or label expansion announcements, but no immediate trading action warranted.
Key Facts
- Presentations at AHS 68th Annual Scientific Meeting, June 4-7 in Orlando, FL
- Four SYMBRAVO data presentations: post-hoc composite efficacy, network meta-analysis vs. gepants, sustained pain relief analysis, and safety endpoint analysis
- No new clinical trial results, regulatory decisions, or financial guidance provided
- SYMBRAVO is already FDA-approved for acute treatment of migraine
Financial Impact
No financial figures disclosed; routine scientific conference update
Risk Factors
- No new efficacy or safety signals disclosed that could change competitive positioning
- Network meta-analysis vs. gepants may not be considered definitive by prescribers
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
3d ago
|
Insider Cluster
| $253.88 awaiting T+1 | awaiting T+1 | — | $255.17 (+0.51%) |
|
Jun 11, 2026
3d ago
|
144
| $253.88 awaiting T+1 | awaiting T+1 | — | $255.17 (+0.51%) |
|
Jun 11, 2026
4d ago
|
Insider Cluster
| $246.42 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.55%) |
|
Jun 9, 2026
5d ago
|
144
| $245.68 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.86%) |
|
Jun 9, 2026
5d ago
|
8-K
| $245.68 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.86%) |
|
Jun 9, 2026
5d ago
|
Insider Cluster
| $245.68 awaiting T+1 | awaiting T+1 | — | $255.17 (+3.86%) |
|
Jun 4, 2026
10d ago
|
Press Release
| $231.48 $232.32 | ▲ +0.36% | ▲ +2.96% | $255.17 (+10.23%) |
|
Jun 3, 2026
11d ago
|
8-K
| $233.49 $231.48 | ▼ −0.86% | ▼ −1.26% | $255.17 (+9.29%) |
|
May 4, 2026
5w ago
|
8-K
| $223.70 $223.06 | ▼ −0.29% | ▼ −1.08% | $255.17 (+14.07%) |
|
May 4, 2026
5w ago
|
Press Release
| $223.70 $223.06 | ▼ −0.29% | ▼ −1.08% | $255.17 (+14.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access